Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)

• Status: Completed
• Trial end date: 2018-09-18
• Target enrollment: 0
• Participant gender: Female

Summary

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®, in ovarian platinum sensitive cancer relapse.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ARCAGY/ GINECO GROUP
• Collaborator: PharmaMar
• Treatments: Doxorubicin; Liposomal doxorubicin; Trabectedin

Criteria

Inclusion Criteria:

• Patients aged 18 years and over,

• Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive Yondelis®-Caelyx® in relapse platinum-sensitive

• Patients should be informed of the study orally and should not have any objection their data to be processed

Exclusion Criteria:

• Patient participation in a clinical trial

• Patient non-affiliated to a social security scheme.